vs

Side-by-side financial comparison of SIFCO INDUSTRIES INC (SIF) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $24.0M, roughly 1.2× SIFCO INDUSTRIES INC). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -71.0%, a 78.5% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 14.8%). SIFCO INDUSTRIES INC produced more free cash flow last quarter ($8.0M vs $-31.8M).

SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

SIF vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.2× larger
ZYME
$27.6M
$24.0M
SIF
Growing faster (revenue YoY)
ZYME
ZYME
+57.8% gap
ZYME
72.6%
14.8%
SIF
Higher net margin
SIF
SIF
78.5% more per $
SIF
7.5%
-71.0%
ZYME
More free cash flow
SIF
SIF
$39.8M more FCF
SIF
$8.0M
$-31.8M
ZYME

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
SIF
SIF
ZYME
ZYME
Revenue
$24.0M
$27.6M
Net Profit
$1.8M
$-19.6M
Gross Margin
21.6%
Operating Margin
10.7%
-80.1%
Net Margin
7.5%
-71.0%
Revenue YoY
14.8%
72.6%
Net Profit YoY
177.3%
34.3%
EPS (diluted)
$0.29
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SIF
SIF
ZYME
ZYME
Q4 25
$24.0M
Q3 25
$22.8M
$27.6M
Q2 25
$22.1M
$48.7M
Q1 25
$19.0M
$27.1M
Q4 24
$20.9M
$31.0M
Q3 24
$21.7M
$16.0M
Q2 24
$22.0M
$19.2M
Q1 24
$20.5M
$10.0M
Net Profit
SIF
SIF
ZYME
ZYME
Q4 25
$1.8M
Q3 25
$-429.0K
$-19.6M
Q2 25
$3.4M
$2.3M
Q1 25
$-1.4M
$-22.6M
Q4 24
$-2.3M
$-23.5M
Q3 24
$-443.0K
$-29.9M
Q2 24
$72.0K
$-37.7M
Q1 24
$-1.6M
$-31.7M
Gross Margin
SIF
SIF
ZYME
ZYME
Q4 25
21.6%
Q3 25
9.6%
Q2 25
26.7%
Q1 25
8.3%
Q4 24
4.4%
Q3 24
10.7%
Q2 24
12.3%
Q1 24
7.3%
Operating Margin
SIF
SIF
ZYME
ZYME
Q4 25
10.7%
Q3 25
-1.7%
-80.1%
Q2 25
14.8%
-1.4%
Q1 25
-4.1%
-94.5%
Q4 24
-9.2%
-71.6%
Q3 24
-1.5%
-213.8%
Q2 24
0.7%
-222.9%
Q1 24
-6.5%
-376.9%
Net Margin
SIF
SIF
ZYME
ZYME
Q4 25
7.5%
Q3 25
-1.9%
-71.0%
Q2 25
15.4%
4.8%
Q1 25
-7.3%
-83.5%
Q4 24
-11.1%
-75.8%
Q3 24
-2.0%
-186.6%
Q2 24
0.3%
-195.8%
Q1 24
-7.8%
-315.6%
EPS (diluted)
SIF
SIF
ZYME
ZYME
Q4 25
$0.29
Q3 25
$-0.07
$-0.26
Q2 25
$0.56
$0.03
Q1 25
$-0.23
$-0.30
Q4 24
$-0.38
$-0.32
Q3 24
$-0.07
$-0.39
Q2 24
$0.01
$-0.49
Q1 24
$-0.27
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SIF
SIF
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$1.1M
$64.8M
Total DebtLower is stronger
$39.0K
Stockholders' EquityBook value
$38.7M
$320.1M
Total Assets
$74.9M
$397.3M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SIF
SIF
ZYME
ZYME
Q4 25
$1.1M
Q3 25
$491.0K
$64.8M
Q2 25
$2.0M
$98.3M
Q1 25
$1.9M
$76.2M
Q4 24
$3.1M
$66.1M
Q3 24
$1.7M
$122.4M
Q2 24
$3.4M
$71.0M
Q1 24
$2.5M
$114.8M
Total Debt
SIF
SIF
ZYME
ZYME
Q4 25
$39.0K
Q3 25
$51.0K
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$3.6M
Q1 24
$4.1M
Stockholders' Equity
SIF
SIF
ZYME
ZYME
Q4 25
$38.7M
Q3 25
$36.9M
$320.1M
Q2 25
$35.8M
$334.5M
Q1 25
$32.4M
$325.0M
Q4 24
$33.7M
$338.8M
Q3 24
$30.4M
$367.0M
Q2 24
$29.8M
$406.2M
Q1 24
$29.7M
$438.0M
Total Assets
SIF
SIF
ZYME
ZYME
Q4 25
$74.9M
Q3 25
$73.4M
$397.3M
Q2 25
$77.3M
$408.4M
Q1 25
$78.8M
$425.5M
Q4 24
$81.0M
$463.1M
Q3 24
$104.6M
$487.2M
Q2 24
$106.3M
$515.6M
Q1 24
$104.2M
$553.8M
Debt / Equity
SIF
SIF
ZYME
ZYME
Q4 25
0.00×
Q3 25
0.00×
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.12×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SIF
SIF
ZYME
ZYME
Operating Cash FlowLast quarter
$8.1M
$-31.4M
Free Cash FlowOCF − Capex
$8.0M
$-31.8M
FCF MarginFCF / Revenue
33.3%
-115.2%
Capex IntensityCapex / Revenue
0.4%
1.5%
Cash ConversionOCF / Net Profit
4.51×
TTM Free Cash FlowTrailing 4 quarters
$11.5M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SIF
SIF
ZYME
ZYME
Q4 25
$8.1M
Q3 25
$726.0K
$-31.4M
Q2 25
$371.0K
$12.1M
Q1 25
$2.8M
$-3.4M
Q4 24
$-3.8M
$-41.5M
Q3 24
$857.0K
$-5.9M
Q2 24
$382.0K
$-25.0M
Q1 24
$-3.2M
$-37.7M
Free Cash Flow
SIF
SIF
ZYME
ZYME
Q4 25
$8.0M
Q3 25
$566.0K
$-31.8M
Q2 25
$310.0K
$11.6M
Q1 25
$2.7M
$-3.4M
Q4 24
$-3.9M
$-41.8M
Q3 24
$580.0K
$-6.8M
Q2 24
$-175.0K
$-25.6M
Q1 24
$-3.9M
$-37.9M
FCF Margin
SIF
SIF
ZYME
ZYME
Q4 25
33.3%
Q3 25
2.5%
-115.2%
Q2 25
1.4%
23.7%
Q1 25
14.1%
-12.6%
Q4 24
-18.8%
-134.8%
Q3 24
2.7%
-42.4%
Q2 24
-0.8%
-133.0%
Q1 24
-18.9%
-377.5%
Capex Intensity
SIF
SIF
ZYME
ZYME
Q4 25
0.4%
Q3 25
0.7%
1.5%
Q2 25
0.3%
1.1%
Q1 25
0.8%
0.1%
Q4 24
0.5%
1.0%
Q3 24
1.3%
5.6%
Q2 24
2.5%
3.1%
Q1 24
3.3%
1.8%
Cash Conversion
SIF
SIF
ZYME
ZYME
Q4 25
4.51×
Q3 25
Q2 25
0.11×
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
5.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SIF
SIF

Fixed Wing Aircraft Revenue$10.5M44%
Commercial Revenue$8.7M36%
Commercial Product And Other Revenue$2.8M12%
Commercial Space$1.1M5%
Other$840.0K4%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons